CompletedNot Applicable

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

Italy95 participantsStarted 2023-05-05

Plain-language summary

This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with chronic ITP who are refractory to other treatments and who received Fostamatinib according to standard clinical practice between October 1st, 2021 and April 1st, 2023
✓. Age greater or equal to 18 years at the treatment start
✓. Signed written informed consent document (if feasible) according to ICH/EU/GCP and national local laws

Exclusion criteria

✕. Contraindications or hypersensitivity to Fostamatinib, its active substance or any of its excipients
✕. Patients participating in an interventional clinical trial at the time of enrollment.

What they're measuring

Number of ITP patients who receive Fostamatinib

Timeframe: 6 months

Trial details

NCT IDNCT05613296

SponsorGruppo Italiano Malattie EMatologiche dell'Adulto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-05-31

View on ClinicalTrials.gov More ITP - Immune Thrombocytopenia trials